Page 481 - Binder2

(pg. 463) World Health Organization. (2021). Local
production for access to medical products: Developing a
framework to improve public health.
https://www.who.int/publications/i/item/9789240020881

(pg. 372) Mattingly, T. J., & Hughes, T. D. (2020).
Community pharmacy as a site of care: Evidence and
implications. Journal of the American Pharmacists
Association, 60(1), 10–13.
https://doi.org/10.1016/j.japh.2019.11.002

(pg. 216) Alpern, J. D., & Kesselheim, A. S. (2017). The
$300,000 drug pricing dilemma—A public policy
perspective. New England Journal of Medicine, 376(20),
1806–1809. https://doi.org/10.1056/NEJMp1701980

(pg. 73) Hwang, T. J., Jain, N., & Kesselheim, A. S. (2021).
Access to high-priced biologics—Industry practices and
regulatory reform. Health Affairs, 40(5), 687–693.
https://doi.org/10.1377/hlthaff.2020.02025

(pg. 211) Tacket, C. O., et al. (2004). Human immune
responses to a novel Norwalk virus vaccine delivered in
transgenic potatoes. The Lancet, 362(9387), 213–217.
https://doi.org/10.1016/S0140-6736(03)15368-1

(pg. 360) Kwon, K. C., Verma, D., Singh, N. D., Herzog,
R., & Daniell, H. (2013). Oral delivery of human
biopharmaceuticals, autoantigens and vaccine antigens
bioencapsulated in plant cells. Advanced Drug Delivery
Reviews, 65(6), 782–799.
https://doi.org/10.1016/j.addr.2012.09.005

479